Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Istanbul Bakirkoy Maternity and Children Diseases Hospital

Status and phase: Completed; Phase 4

Conditions: Pelvic Inflammatory Disease

Treatments: Drug: Moxifloxacin; Drug: Ofloxacin; Drug: Metronidazole

Study type: Interventional

Funder types: Other

Identifiers

NCT01799356

Asicioglu03

treatment uPID (Other Identifier)

treatment (Other Identifier)

Details and patient eligibility

About

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Enrollment: 1,303 patients

Sex: Female

Ages: 14 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Women diagnosed uncomplicated PID
2. Patients age are between 14 with 45
3. Pelvic tenderness and vaginal discharge

Exclusion criteria

1. Urinary Tract Enfections
2. Tubo-ovarian abscess and complicated PID
3. Hıstory of antibiotics treatment
4. Other pelvic pain causes
5. Endometriosis
6. Delivery,abortion and surgery within last months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

1,303 participants in 2 patient groups, including a placebo group

moxifloxacin Group

Active Comparator group

Description:

Treatment at uPID with moxifloxacin

Treatment:

Drug: Moxifloxacin

Ofloxacin Group

Placebo Comparator group

Description:

Treatment at uPID with Ofloxacin plus metronidazole

Treatment:

Drug: Metronidazole

Drug: Ofloxacin